First Subject Dosed In Cellarity’s Trial Of CLY-124 For SCD - Data Intelligence

Over 20 lakh from tribal areas screened for sickle cell anaemia

More than 20 lakh people from tribal areas have been screened since we started the sickle cell anaemia project eight years back, said CSIR's Director General Nallathamby Kalaiselvi, terming it among the institute's more successful missions.

First Subject Dosed In Cellarity’s Trial Of CLY-124 For SCD - Data Intelligence

Sickle cell disease leads to pain crises, chronic inflammation, and organ damage. Credit: Yuriy K/Shutterstock. Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD). This development follows the US Food and Drug Administration’s (FDA) clearance of the company’s investigational new drug application. The global trial will evaluate the tolerability, pharmacokinetic, and safety prof…

First subject dosed in Cellarity’s trial of CLY-124 for sickle cell disease

Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).The post First subject dosed in Cellarity’s trial of CLY-124 for sickle cell disease appeared first on Clinical Trials Arena.

Level of physical activity tied to less pain in SCD: Senegal Study

Most people with sickle cell disease (SCD) seem to meet or exceed current physical activity recommendations for the general population, a recent study in Senegal shows. Notably, greater step counts and time spent in more intense activities were associated with lower pain frequency and intensity, as well as lower blood viscosity, which refers to higher blood thickness due to the clumping of red blood cells. These benefits may reduce the risk of v…